Validea Detailed Fundamental Analysis

Validea's Multi-Factor Investor model, based on Pim van Vliet's low-volatility strategy, assigned Medtronic (MDT) a 75% rating, which falls below the 80% threshold for 'some interest.' While MDT met criteria for market cap and low standard deviation, its neutral momentum and net payout yield led to a 'FAIL' on the final rank, indicating it does not strongly align with this specific factor-based investment profile.

Analysis

Medtronic PLC (MDT) was evaluated using Validea's Multi-Factor Investor model, which is based on Pim van Vliet's strategy favoring low-volatility stocks with strong momentum and high net payout yields. The company achieved a score of 75%, falling below the 80% threshold that indicates strategic interest. While MDT, a large-cap medical supplies firm, successfully passed the model's screens for market capitalization and low standard deviation, it demonstrated weakness in other key areas. The stock was rated as "NEUTRAL" on both its "Twelve Minus One Momentum" and "Net Payout Yield" factors. Consequently, these neutral readings on critical secondary criteria led to a final rank of "FAIL," indicating that MDT does not currently align with the specific profile sought by this quantitative, low-risk factor strategy.

Key Decisions for Investors

• Investors employing a multi-factor strategy similar to Pim van Vliet's should note that MDT currently fails to meet the combined criteria for momentum and net payout yield, despite its favorable low-volatility profile.
• Current or prospective holders of MDT should monitor its momentum indicators and capital return policies, as the stock's neutral performance in these areas represents a key weakness identified by this quantitative screen.
• While the stock fails the overall multi-factor model, investors whose primary objective is to gain exposure to low-volatility equities may still find MDT's attributes appealing, given it passed the model's standard deviation test.